References
- Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-22.
- Mellor JA, Kingdom J, Cafferkey M, Keane CT. Vancomycin toxicity: a prospective study. J Antimicrob Chemother 1985; 15: 773 80.
- Davey PG, Williams AH. A review of the safety profile of teicoplanin. J Antimicrob Chemother 1991; 27: Suppl. B, 69-73.
- Chow AW, Azar RM. Glycopeptides and nephrotoxicity. Int Care Med 1994; 20: S23-S29.
- Ryback MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxocity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-87.
- Kureishi A, Jewesson PJ, Rubinger M, et al. Doubleblind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother 1991; 35: 2246-52.
- Charbonneau P, Harding I, Garaud JJ, Aubertin J, Brunet F, Domart Y. Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients. Intensive Care Med 1994; 20: Suppl. 4, S35-S42.
- Brummett RE, Fox KE. Vancomycin and erythromycin induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 791-6.
- Wilson APR. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents 1998; 10: 143-52.
- Wilson APR, Grüneberg RN, Neu H. A critical review of the dose of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; 4: Suppl 1, S1-S30.
- Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 1985; 16: 235-41.
- Lewis P, Garaud JJ, Parenti F. A multicentre open clinical trial of teicoplanin in infections caused by Gram-positive bacteria. J Antimicrob Chemother 1988; 21: Suppl A, 61-7.
- Davenport A. Allergic cross-reactivity to teicoplanin and vancomycin. Nephron 1993; 63: 482.
- Polk RE. Anaphylactoid reactions to glycopeptide antibiotics. J Antimicrob Chemother 1991; 27: Suppl., 17- 29.
- Dubettier S, Boibieux A, Lagable M, Crevon L, Peyramond D, Milon H. Red man syndrome with teicoplanin. Rev Infect Dis 1991; 12: 770.
- de Vries E, van Weel-Sipman MH, Vossen JM. A four year old child with teicoplanin allergy but no evidence of cross-reaction with vancomycin. Ped Infect Dis J 1994; 13: 167.
- Wang L, Liu C, Wang F, Fung C, Chiu Z. Cheng D. Chromatographically purified vancomycin therapy of serious infections caused by Staphylococcus aureus and other Grampositive bacteria. Clin Ther 1988; 10: 574-84.
- Killian AD, Sahai JV, Memish ZA. Red man syndrome after oral vancomycin. Ann Int Med 1991; 115: 410-1.
- Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, aetiology and prophylaxis. J Infect Dis 1991; 164: 1180-5.
- Sahai J, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk R. Comparison of vancomycin- and teicoplanin-induced histamine release and 'red man syndrome'. Antimicrob Agents Chemother 1990; 34: 765-9.
- Ryback MJ, Bailey EM, Warbasse LH. Absence of 'red man syndrome' in patients being treated with vancomycin or high-dose teicoplanin. Antimicrob Agents Chemother 1992; 36: 1204-7.
- Wilson APR, Grüneberg RN. In: 'Teicoplanin: the first decade', The Medicine Group (Education) Ltd, Abingdon, 1997.
- Garrelts JC, Worst WD, Silkey B, Gagnon S. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 1994; 14: 438-45.
- Gyssens IC, van der Meer JWM, Lennards CA, Hekstar YA. Cost of hospital antimicrobial therapy. A method for global cost calculation. Pharm Weekly Sci 1991; 13: 248-53.
- Janknegt R. Teicoplanin in perspective. A critical comparison with vancomycin. Pharm Weekly Sci 1991; 13: 153- 60.